3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Status
Completed
31
Recruiting
7
Terminated
6
Withdrawn
3
Active not recruiting
3
Unknown
2
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Head & Neck
19
Sarcoma
4
Gynecologic
4
Gastrointestinal
4
Thoracic
3
Genitourinary
3
Endocrine
3
Breast
3
NET
2
Dermatologic
2
CNS
2
Other solid neoplasm
1
Lymphoid
1
Conditions
Prostatic Neoplasms
501
Carcinoma, Renal Cell
164
Urinary Bladder Neoplasms
135
Carcinoma, Transitional Cell
71
Carcinoma, Non-Small-Cell Lung
57
Kidney Neoplasms
55
Melanoma
53
Breast Neoplasms
51
Ovarian Neoplasms
43
Neoplasms
41
Neoplasm Metastasis
40
Colorectal Neoplasms
38
Lung Neoplasms
27
Squamous Cell Carcinoma of Head and Neck
26
Non-Muscle Invasive Bladder Neoplasms
26
Uterine Cervical Neoplasms
25
Stomach Neoplasms
25
Sarcoma
24
Endometrial Neoplasms
24
Triple Negative Breast Neoplasms
21
Pancreatic Neoplasms
19
Esophageal Neoplasms
18
Carcinoma, Hepatocellular
17
Wilms Tumor
16
Head and Neck Neoplasms
16
Small Cell Lung Carcinoma
15
Urologic Neoplasms
14
Colonic Neoplasms
14
Urethral Neoplasms
13
Ureteral Neoplasms
13
Interventions
entrectinib
2
pembrolizumab
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Active not recruiting
×
Salivary Gland Neoplasms
×
Genitourinary
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA
NCT04140526
2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2
Active not recruiting
733 enrolled